HSPMdb Accession No | HSPMDB001447 |
PMID | 28615625 |
Target | Hsp70 |
HSP Name | Hsc70 (HSPA8) |
Organism | Human |
Localization | Cytosol and nucleus |
Cellular activity | Antiproliferative activity |
Compound Name | Az-amide-GD |
IUPAC Name | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate |
SMILES | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |
Class | Hybrid of HSP70 and HSP90 inhibitor |
IC50 (µM) | >10 |
Site of Interaction | Nucleotide binding domain |
Cellular assay | MTT viability assay |
Cellular Model | HL60 |
Disease | Cancer |